eosinophilic myocarditis
Recently Published Documents


TOTAL DOCUMENTS

282
(FIVE YEARS 97)

H-INDEX

21
(FIVE YEARS 3)

2021 ◽  
Author(s):  
Masahiko Takeda ◽  
Naoki Ishio ◽  
Toshihiro Shoji ◽  
Naoto Mori ◽  
Moe Matsumoto ◽  
...  

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Jiayi Wu ◽  
Wei Tang ◽  
Shiyi Zhou ◽  
Youjia Yu ◽  
Zhiwei Zhang ◽  
...  

Author(s):  
Ludovica Blumetti ◽  
Maria Luisa de Perna ◽  
Michael Reinehr ◽  
Giovanni Pedrazzini

Abstract BACKGROUND Eosinophilic myocarditis (EM) is a rare and potentially life-threatening form of myocarditis, frequently (but not always) associated with eosinophilia, and presents with acute chest pain, or signs and symptoms of acute or chronic heart failure. EM has various aetiologies, including eosinophilic granulomatosis with polyangiitis (EGPA). CASE SUMMARY A 52-year-old female with a long-standing history of asthma, acral paraesthesia, subcutaneous nodules and recurrent chest pain treated with anti-inflammatory drugs, was admitted to our hospital with chest pain, repolarization disturbances, eosinophilia and increased troponin levels. After an initial evaluation by coronary angiography, echocardiography and cardiac magnetic resonance, a definitive diagnosis of eosinophilic myocarditis was made with the help of an endomyocardial biopsy. The aetiological diagnosis of EM as a manifestation of tissue involvement in eosinophilic granulomatosis with polyangiitis (EGPA) was concluded after ruling out other possible causes of eosinophilia and with the help of other diagnostic criteria for EGPA (asthma, eosinophilia and neuropathy). Therefore, we started with a high dosage of glucocorticoids, and attained relief of symptoms and normalization of eosinophilic count after a few days. DISCUSSION In cases of myocarditis (particularly if associated with eosinophilia), EM is a manifestation of EGPA and should be considered for a prompt differential diagnosis. Endomyocardial biopsy represents the gold standard for the diagnosis of EM. The mainstay of therapy for EM is immunosuppressive drugs to help prevent its evolution to a fulminant form and chronic progression towards restrictive cardiomyopathy.


CHEST Journal ◽  
2021 ◽  
Vol 160 (4) ◽  
pp. A6
Author(s):  
Kendall Creed ◽  
Navkiran Randhawa ◽  
Victor Test ◽  
Sabrina Siddiqui

CHEST Journal ◽  
2021 ◽  
Vol 160 (4) ◽  
pp. A198
Author(s):  
Arnaldo Rodriguez ◽  
Dorys Chavez Melendez ◽  
Karan Amlani ◽  
Leo Shimanovich ◽  
Mariam Farhan

Sign in / Sign up

Export Citation Format

Share Document